Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
Chimeric antigen receptor (CAR) therapies such as tisagenlecleucel, indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukemia (ALL), have been associated with striking treatment outcomes and overall survival. Yet, they are also associated with unique...
Main Authors: | Avis Harden, Dristhi Ragoonanan, Daryl Anildes-Gubman, David McCall, Kathleen Faltus, Sarah Featherston, Basirat Shoberu, Jerelyn R. Moffet, Demetrios Petropoulos, Sajad J. Khazal, Shehla Razvi, Kris M. Mahadeo, Priti Tewari |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.01227/full |
Similar Items
-
Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
by: Castaneda-Puglianini O, et al.
Published: (2021-08-01) -
Cytokines in CAR T Cell–Associated Neurotoxicity
by: Juliane Gust, et al.
Published: (2020-12-01) -
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
by: Joseph W. Fischer, et al.
Published: (2021-06-01) -
Editorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy
by: Beatriz Martín-Antonio
Published: (2021-03-01) -
Propriétés électriques bistables des motoneurones de la moelle épinière : Identification des mécanismes ioniques sous-jacents
by: Bouhadfane, Mouloud
Published: (2014)